ribozyme

Framycetin sulfate (Neomycin Sulphate B) belongs to aminoglycoside class of antibiotics that contain two or more aminosugars connected by glycosidic bonds.

5-Fluorouridine is a metabolite of 5-fluorouracil that inhibits rRNA synthesis in human colon cancer cells and exhibits antitumor and antiviral activity. 5-Fluorouridine exerts a cytotoxic effect on the growth of L1210 cells, with an IC₅₀ value of 2 nM. 5-Fluorouridine binds to poly-A RNA and exhibits antiproliferative activity. 5-Fluorouridine can be used in studies of nucleic acid metabolism, cancer chemotherapy, and viral replication mechanisms.

Framycetin is an aminoglycoside antibiotic and it also inhibits hammerhead ribozyme (Ki: 13.5 μM).

Viomycin is a member of the tuberactinomycin family of antibiotics. Viomycin also inhibits group I intron splicing and prokaryotic protein synthesis. Freezes bacterial ribosomes in either the pre- or post-translational state. Facilitates trans-cleavage of

Glucosamine 6-sulfate (GlcN6S) is a glucosamine derivative exhibiting anti-inflammatory effects in experimental autoimmune encephalomyelitis (EAE). It inhibits gene expression of IL-12, T-bet, and IFN-γ, suppresses Th1 CD4 T cell differentiation, and may be utilised in multiple sclerosis (MS) research.

DMTr-4'-Methyluridine-CED-TBDMS phosphoramidite, a dye reagent for oligonucleotide labeling, serves as a pivotal tool in RNA therapeutic research, RNA aptamer development, and ribozyme studies aimed at RNA structure elucidation. This compound offers broad utility as a probe for uncovering RNA structure complexities. For optimal preservation, it should be stored away from light.

Framycetin-d2 (Neomycin B-d2) is a deuterium-labeled version of Framycetin. Framycetin (Neomycin B), an aminoglycoside antibiotic, effectively inhibits RNase P cleavage activity with a Ki of 35 μM by competing for specific divalent metal ion binding sites on RNase P RNA. It also hinders hammerhead ribozyme action, possessing a Ki of 13.5 μM. Framycetin serves as a precursor for 5″-azido neomycin B that binds to the Drosha site in miR-525 and can be applied in the treatment of hepatic encephalopathy and infections caused by enteropathogenic Escherichia coli.